Your browser doesn't support javascript.
loading
Flavonoids from Pterogyne nitens as Zika virus NS2B-NS3 protease inhibitors.
Lima, Caroline Sprengel; Mottin, Melina; de Assis, Leticia Ribeiro; Mesquita, Nathalya Cristina de Moraes Roso; Sousa, Bruna Katiele de Paula; Coimbra, Lais Durco; Santos, Karina Bispo-Dos-; Zorn, Kimberley M; Guido, Rafael V C; Ekins, Sean; Marques, Rafael Elias; Proença-Modena, José Luiz; Oliva, Glaucius; Andrade, Carolina Horta; Regasini, Luis Octavio.
Afiliação
  • Lima CS; Laboratory of Antibiotics and Chemotherapeutics (LAQ), Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (Unesp), São José do Rio Preto, SP, Brazil.
  • Mottin M; Laboratory of Molecular Modeling and Drug Design (LabMol), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO, Brazil.
  • de Assis LR; Laboratory of Antibiotics and Chemotherapeutics (LAQ), Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (Unesp), São José do Rio Preto, SP, Brazil.
  • Mesquita NCMR; Institute of Physics of São Carlos, University of São Paulo, São Carlos, SP, Brazil.
  • Sousa BKP; Laboratory of Molecular Modeling and Drug Design (LabMol), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO, Brazil.
  • Coimbra LD; Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, SP, Brazil.
  • Santos KB; Laboratory of Emerging Viruses (LEVE), Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil.
  • Zorn KM; Collaborations Pharmaceuticals, Inc., Raleigh, NC, United States.
  • Guido RVC; Institute of Physics of São Carlos, University of São Paulo, São Carlos, SP, Brazil.
  • Ekins S; Collaborations Pharmaceuticals, Inc., Raleigh, NC, United States.
  • Marques RE; Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, SP, Brazil.
  • Proença-Modena JL; Laboratory of Emerging Viruses (LEVE), Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil.
  • Oliva G; Institute of Physics of São Carlos, University of São Paulo, São Carlos, SP, Brazil.
  • Andrade CH; Laboratory of Molecular Modeling and Drug Design (LabMol), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO, Brazil. Electronic address: carolina@ufg.br.
  • Regasini LO; Laboratory of Antibiotics and Chemotherapeutics (LAQ), Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (Unesp), São José do Rio Preto, SP, Brazil. Electronic address: luis.regasini@unesp.br.
Bioorg Chem ; 109: 104719, 2021 04.
Article em En | MEDLINE | ID: mdl-33636437
ABSTRACT
Although the widespread epidemic of Zika virus (ZIKV) and its neurological complications are well-known there are still no approved drugs available to treat this arboviral disease or vaccine to prevent the infection. Flavonoids from Pterogyne nitens have already demonstrated anti-flavivirus activity, although their target is unknown. In this study, we virtually screened an in-house database of 150 natural and semi-synthetic compounds against ZIKV NS2B-NS3 protease (NS2B-NS3p) using docking-based virtual screening, as part of the OpenZika project. As a result, we prioritized three flavonoids from P. nitens, quercetin, rutin and pedalitin, for experimental evaluation. We also used machine learning models, built with Assay Central® software, for predicting the activity and toxicity of these flavonoids. Biophysical and enzymatic assays generally agreed with the in silico predictions, confirming that the flavonoids inhibited ZIKV protease. The most promising hit, pedalitin, inhibited ZIKV NS2B-NS3p with an IC50 of 5 µM. In cell-based assays, pedalitin displayed significant activity at 250 and 500 µM, with slight toxicity in Vero cells. The results presented here demonstrate the potential of pedalitin as a candidate for hit-to-lead (H2L) optimization studies towards the discovery of antiviral drug candidates to treat ZIKV infections.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Proteínas Virais / Proteínas não Estruturais Virais / Zika virus Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Proteínas Virais / Proteínas não Estruturais Virais / Zika virus Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article